West Pharmaceutical Services/$WST
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About West Pharmaceutical Services
West Pharmaceutical Services is based in Pennsylvania, US, and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs, which include large molecule biologics, peptides such as GLP-1 receptor agonists, and small molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
Ticker
$WST
Sector
Health
Primary listing
NYSE
Employees
10,600
Headquarters
Website
WST Metrics
BasicAdvanced
$17B
35.98
$6.68
1.09
$0.84
0.37%
Price and volume
Market cap
$17B
Beta
1.09
52-week high
$348.90
52-week low
$187.43
Average daily volume
829K
Dividend rate
$0.84
Financial strength
Current ratio
2.78
Quick ratio
1.852
Long term debt to equity
9.764
Total debt to equity
10.522
Dividend payout ratio (TTM)
12.32%
Interest coverage (TTM)
180.94%
Profitability
EBITDA (TTM)
795.6
Gross margin (TTM)
35.27%
Net profit margin (TTM)
16.48%
Operating margin (TTM)
21.39%
Effective tax rate (TTM)
20.21%
Revenue per employee (TTM)
$280,000
Management effectiveness
Return on assets (TTM)
10.64%
Return on equity (TTM)
17.72%
Valuation
Price to earnings (TTM)
35.984
Price to revenue (TTM)
5.891
Price to book
5.9
Price to tangible book (TTM)
6.16
Price to free cash flow (TTM)
50.695
Free cash flow yield (TTM)
1.97%
Free cash flow per share (TTM)
4.745
Dividend yield (TTM)
0.35%
Forward dividend yield
0.37%
Growth
Revenue change (TTM)
2.90%
Earnings per share change (TTM)
-5.00%
3-year revenue growth (CAGR)
0.36%
10-year revenue growth (CAGR)
7.77%
3-year earnings per share growth (CAGR)
-9.33%
10-year earnings per share growth (CAGR)
14.74%
3-year dividend per share growth (CAGR)
5.34%
10-year dividend per share growth (CAGR)
6.80%
What the Analysts think about WST
Analyst ratings (Buy, Hold, Sell) for West Pharmaceutical Services stock.
Bulls say / Bears say
West Pharmaceutical Services raised its annual profit forecast for 2025, citing benefits from a weaker U.S. dollar and anticipated strong demand for medical devices. The company now projects adjusted earnings between $6.15 and $6.35 per share, up from its previous estimate of $6 to $6.20. (reuters.com)
The company reported first-quarter 2025 sales of $698 million, slightly above estimates, and an adjusted quarterly profit of $1.45 per share, exceeding expectations of $1.23. (reuters.com)
West Pharmaceutical Services has been anticipating growth in sales due to increased demand for components used in the packaging of treatments, including Novo Nordisk's diabetes drug Ozempic, weight-loss drug Wegovy, and Eli Lilly's diabetes drug Mounjaro. (reuters.com)
West Pharmaceutical Services cut its annual profit and sales forecast in July 2024 due to lower demand for its medical equipment used in making injectable drugs, as biotech customers worked through their existing inventories. The company now expects 2024 profit in the range of $6.35 to $6.65 per share, down from its previous forecast of $7.63 to $7.88. (reuters.com)
The company's second-quarter 2024 sales fell about 7% to $702.1 million, missing analysts' ... . On an adjusted basis, the company ... quarter ended June 30, ... . (reuters.com)
West Pharmaceutical Services' full-year 2025 revenue guidance of $2.89 billion at the midpoint came in 5% below analysts' estimates, and its adjusted EPS guidance for the upcoming financial year is $6.10 at the midpoint, missing analyst estimates by 17.8%. (stockstory.com)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.
WST Financial Performance
Revenues and expenses
WST Earnings Performance
Company profitability
WST News
AllArticlesVideos
West Pharma raises annual profit forecast on strong demand for its drug components
Reuters·2 weeks ago
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of West Pharmaceuticals
Business Wire·1 month ago
Deadline Soon: West Pharmaceutical Services, Inc. (WST) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
Nov12
West Pharmaceutical Services
Dividend·Ex-dividend
Nov19
West Pharmaceutical Services
Dividend·Payment
$0.22Per share
FAQs
What’s the current market cap for West Pharmaceutical Services stock?
West Pharmaceutical Services (WST) has a market cap of $17B as of August 08, 2025.
What is the P/E ratio for West Pharmaceutical Services stock?
The price to earnings (P/E) ratio for West Pharmaceutical Services (WST) stock is 35.98 as of August 08, 2025.
Does West Pharmaceutical Services stock pay dividends?
Yes, the West Pharmaceutical Services (WST) stock pays dividends to shareholders. As of August 08, 2025, the dividend rate is $0.84 and the yield is 0.37%. West Pharmaceutical Services has a payout ratio of 12.32% on a trailing twelve-month basis.
When is the next West Pharmaceutical Services dividend payment date?
The next West Pharmaceutical Services (WST) dividend payment is scheduled for November 19, 2025.
What is the beta indicator for West Pharmaceutical Services?
West Pharmaceutical Services (WST) has a beta rating of 1.09. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.